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A B S T R A C T
Objective: This study aimed to evaluate safety and eﬃcacy of sodium oxybate (SXB) titrated to effect.
Methods: SXB-naive patients who had participated in a randomized SXB clinical trial and had not been
titrated to adequate clinical effect were initiated on open-label SXB at 4.5 g/night and titrated in 1.5-g
increments to 6, 7.5, or 9 g/night or down to 3 g/night, based on individual clinical response. Treatment
was 12 weeks; safety was the primary outcome. Eﬃcacy was evaluated using the Narcolepsy Symptom
Assessment Questionnaire (NSAQ), a ﬁve-point scale (“much improved” to “much worse”) that assessed
changes from baseline in speciﬁc symptoms. Response was deﬁned as “much improved” or “somewhat
improved” overall at weeks 6 and 12.
Results: Of 202 patients, 171 (85%) completed treatment; ﬁnal doses were 3 g (n = 5), 4.5 g (n = 29), 6 g
(n = 80), 7.5 g (n = 66), and 9 g (n = 22). Adverse events (AEs) were reported in 114 patients (56%), serious
AEs in ﬁve (2%). The most common AEs were nausea (10%), headache (7%), and dizziness (5%). Response
rate was 92% at week 6 and 90% at week 12; most patients reported improvements in all individual symp-
toms. Overall, 60% of patients rated their symptoms at 12weeks as “much improved,” and this improvement
was dose dependent.
Conclusions: The SXB safety proﬁle was consistent with parent trials. Ninety percent of patients
reported improvements as measured by the NSAQ.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
Narcolepsy, a chronic neurologic disease, is under-recognized in the
clinical setting [1,2] despite advances in the understanding of its eti-
ology and pathophysiology [3,4]. Narcolepsy is associated with high
medical and psychiatric comorbidity burdens [5,6] as well as a sub-
stantial socioeconomic burden resulting from increased health-care
resource utilization, reduced daily function, poorer quality of life, and
lower productivity relative to those without narcolepsy [7–11].
Narcolepsy is characterized by a pentad of symptoms that in-
cludes cataplexy, excessive daytime sleepiness (EDS), disturbed
nighttime sleep (DNS), hypnagogic/hypnopompic hallucinations, and
sleep paralysis [12]. Although cataplexy is pathognomic for narcolep-
sy, it is not uniformly present, occurring in approximately 70% of
narcolepsy patients, and its absence increases the challenge of diag-
nosis [13]. In contrast, EDS, which is most often the ﬁrst presenting
symptom, is present in all patients with narcolepsy. DNS is a frequent
complaint and has been reported to be present inmost narcolepsy pa-
tients [14]; the symptoms of hallucinations and sleep paralysis are of
variable prevalence and can contribute to disturbed sleep.
Because narcolepsy has an early onset, generally during child-
hood or early adulthood [15,16], and the disease is lifelong with no
cure, patientmanagement relies on a variety of pharmacologic thera-
pies that target speciﬁc symptoms [17]. Sodium oxybate (SXB), the
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sodium salt of gamma hydroxybutyrate, which is an endogenous
metabolite of gamma-aminobutyric acid, is a central nervous system
depressant that is indicated in the US for the treatment of both cata-
plexy and EDS associated with narcolepsy [18]. SXB has also been
reported to impact other narcolepsy symptoms and features [19–21].
The eﬃcacy of SXB for reducing cataplexy attacks and improv-
ing EDSwas demonstrated in pivotal clinical trials [22–24]. However,
placebo-controlled treatment duration in these trials was only up
to 8 weeks, and patients were not necessarily titrated to clinical
effect. The purpose of this study was to provide an open-label treat-
ment extension to evaluate SXB over a longer period of time (12
weeks) among patients who were either naive to SXB or were not
titrated to adequate response in clinical trials.
2. Methods
2.1. Design and patients
This 12-week, multicenter, open-label treatment study en-
rolled patients with a history of narcolepsy with cataplexy whowere
SXB-naive or had participated in one of three randomized clinical
trials of SXB and had not been titrated to adequate clinical effect
[19,22,24]. The study was performed in accordance with the Dec-
laration of Helsinki, and the protocol received approval from the
appropriate Institutional Review Board or Ethics Committee of the
participating centers; all patients providedwritten informed consent
prior to participation.
Other inclusion criteria were age ≥16 years; a history of daytime
sleepiness; had not taken any investigational therapy, with the ex-
ception of SXB within 30 days prior to screening; and if female, was
surgically sterile, two years post-menopausal, or if of childbearing
potential, used a medically accepted method of birth control and
agreed to continue use of this method for the duration of the study.
Exclusion criteria were the presence of any condition that would
place the patient at risk during the study or compromise study com-
pletion or accurate collection of subjective responses; history of
substance use disorder within the past year; history of seizure dis-
order, head trauma, or intracranial surgery; and taking hypnotics,
tranquilizers, antihistamines (except for non-sedating antihista-
mines), anticonvulsants, or clonidine at the start of treatment. All
patients provided written informed consent prior to participation
in the study.
All patients in the current study were initially treated with oral
SXB at 4.5 g/night, given in two equally divided doses 2.5–4 h apart,
and titrated in 1.5-g increments to 6, 7.5, or 9 g/night or down to
3 g/night, with dose adjustments every two weeks. Patients were
allowed to continue stable doses of stimulants for EDS and of tri-
cyclic or selective serotonin reuptake inhibitor antidepressants for
cataplexy.
2.2. Outcomes
Safety and tolerability were evaluated based on the incidence
of adverse events (AEs) throughout the study, and on clinical lab-
oratory assessments and vital sign measurements that were
measured at every 6-week visit.
Eﬃcacy was evaluated subjectively using the Narcolepsy
Symptom Assessment Questionnaire (NSAQ; see supplementaryma-
terial). The NSAQ is an unvalidated patient-reported outcome
that assesses changes in the patient’s overall narcolepsy status as
well as in individual symptoms. A similar questionnaire was used
previously in a small pilot study of SXB [19]. The recall period of
the questionnaire is the past week, and the questionnaire consists
of one question on the overall condition and 6 items reﬂecting in-
dividual symptoms of cataplexy (“Number of cataplexy attacks”);
EDS (“Number of daily inadvertent naps or sleep attacks” and
“Severity of daytime sleepiness”); DNS (“Number of awakenings at
night”); hypnagogic hallucinations (“Number of hypnagogic hallu-
cinations”); and sleep paralysis (“Number of sleep paralysis
episodes”). There are also two additional items, one that assesses
sleep quality (“Quality of sleep at night”) and one that evaluates
concentration (“Ability to concentrate”).
The overall condition is rated on a ﬁve-point Likert-type scale
that ranges from “Much improved” to “Much worse.” The six indi-
vidual items on the core narcolepsy symptom pentad are rated as
“Increased,” “Decreased,” or “Remains the same.” The other two items
are rated using the same scale as for the overall condition. The NSAQ
was administered at 6 and 12 weeks, with responses relative to the
patient’s symptoms during the week before initiating treatment
(baseline).
2.3. Statistical analysis
The safety population represents all patients who received at least
one dose of study drug, and the eﬃcacy analysis was based on the
intent-to-treat population, deﬁned as patients who received at least
one dose of study drug and completed baseline and at least one post-
baseline NSAQ. Unless otherwise speciﬁed, all analyses were based
on the ﬁnal dose that the patient was taking. Baseline demograph-
ic and clinical variables were analyzed using one-way analysis of
variance for continuous variables and chi-square test for categor-
ical variables. The primary outcomes of safety and tolerability are
reported as incidence of AEs and no statistical inferences weremade.
For eﬃcacy evaluation, the proportion of patients who re-
sponded to treatment was determined at week 6 and week 12, with
responders deﬁned as those who reported overall symptoms on the
NSAQ as “much improved” or “somewhat improved” relative to base-
line. Fisher’s exact test was used to compare the responder rates
among treatments by last dosage, and also in a post hoc analysis
to evaluate the proportion of patients across doses who reported
“much improved.” The proportions of patients who reported im-
provements on individual items of the NSAQ were determined.
3. Results
3.1. Disposition and demographics
A total of 202 patients enrolled in the study and 171 (85%) com-
pleted treatment; all patients were included in the safety analysis
and 171 patients comprised the intent-to-treat population. The
primary reasons for discontinuation were AEs (4%), patient non-
compliance (3%), lost to follow-up (1%), protocol departure (1%), and
other (4%). Sixty-ﬁve percent of patients were female and the mean
age at baseline was similar across groups based on ﬁnal dose
(41.9 ± 14.9 years overall; Table 1). While baseline height and weight
were signiﬁcantly different across ﬁnal doses (both p < 0.05), body
mass index (BMI) was not signiﬁcantly different (p = 0.090), al-
though larger patients were generally titrated to higher doses.
Sympathomimetic stimulants were the most common concomi-
tant medication received during the study, and were taken by 87%
of patients.
3.2. Study SXB doses
Dose assessments were recorded every 2 weeks for each patient,
with doses adjusted as necessary to optimize eﬃcacy and toler-
ability. The greatest number of patients received 6 g/night of SXB
as their optimized dose (n = 80; 40%), followed by 7.5 g/night (n = 66;
33%), 4.5 g (n = 29; 14%), and 9 g (n = 22; 11%), with the 3-g dose
taken by the fewest patients (n = 5; 2%). A total of 966 dose assess-
ments were conducted, and of these, 30% resulted in a dose increase,
4% in a dose decrease, and the majority (66%) remained unchanged.
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Most (95%) of the dose increases were due to insuﬃcient re-
sponse (the reasons for the remaining 5% of increased doses were
not recorded), and while decreases in dose were mainly due to AEs
(45%), in 43% of decreases, the reason for the decreased dose was
not captured.
3.3. Safety and tolerability
As shown in Table 2, 56% of patients reported AEs. Nine pa-
tients discontinued due to a variety of AEs that included psychosis,
migraine headache, dizziness, nausea, anxiety, fatigue, insomnia, ab-
dominal pain, shortness of breath, and depression. Five patients had
serious AEs, and two of these were serious AEs that were consid-
ered treatment related: headache in a patient taking 7.5 g/night who
continued with study participation, and psychosis in a patient taking
9 g/night who discontinued treatment. Most AEs were considered
by the investigators to be of mild or moderate severity. The most
common AEs were nausea (10%), headache (7%), and dizziness (5%),
and did not appear to be dose related (Table 2).
Overall changes in laboratory results were minimal and ap-
peared to be unrelated to dose. No trends were observed for the
few changes in vital signs or physical examination variables that
were reported.
3.4. Eﬃcacy
Based on the response criterion of “much improved” or “some-
what improved” relative to baseline for overall symptoms on the
NSAQ, 92% of all patients were rated as treatment responders at week
6, and 90% were responders at week 12. The response rate among
patients across treatment doses was similar at the two time points
(Fig. 1). At week 6, 54% of all patients reported being “much im-
proved,” and 60% at week 12 (Fig. 1). The post hoc analysis showed
that the proportion of patients who rated their symptoms as “much
Table 1
Demographic characteristics of the population by last dose of SXB.
Variable SXB 3 g (n = 5) SXB 4.5 g (n = 29) SXB 6 g (n = 80) SXB 7.5 g (n = 66) SXB 9 g (n = 22) p
Age, years, mean (SD) 35.6 (12.3) 43.7 (14.2) 41.4 (16.4) 43.4 (13.7) 38.3 (14.4) 0.510
Female, n (%) 5 (100.0) 22 (75.9) 54 (67.5) 41 (62.1) 10 (45.5) 0.079
Weight, kg, mean (SD) 59.4 (11.0) 78.1 (22.5) 84.6 (22.8) 89.0 (19.1) 92.8 (15.0) 0.003
Height, cm, mean (SD) 159.0 (6.9) 164.3 (8.9) 167.5 (8.9) 169.2 (8.4) 171.0 (7.1) 0.006
BMI, kg/m2, mean (SD) 23.4 (3.6) 29.3 (8.7) 29.9 (7.4) 31.4 (7.1) 32.0 (6.5) 0.090
BMI, body mass index; SXB, sodium oxybate.
Table 2
AEs by SXB dose at AE onset.
AE Number of Patients (%)
SXB 3 g (n = 10) SXB 4.5 g (n = 189) SXB 6 g (n = 171) SXB 7.5 g (n = 99) SXB 9 g (n = 27) Total (N = 202)
Any AEa 5 (50) 48 (25) 54 (32) 35 (35) 10 (37) 114 (56)
Severe AEs 1 (10) 5 (3) 7 (4) 4 (4) 0 15 (7)
Serious AEs 0 1 (<1) 2 (1) 1 (1) 1 (4) 5 (2)b
Discontinuations due to AE 0 2 (1) 5 (3) 1 (1) 0 7 (3)c
Treatment-related AEs 3 (30) 25 (13) 34 (20) 19 (19) 8 (30) 74 (37)
Treatment-related serious AEs 0 0 0 1 (1) 1 (4) 2 (1)
Most frequent AEsd
Body as a whole
Headache 1 (10) 3 (2) 6 (4) 3 (3) 2 (7) 14 (7)
Pain 1 (10) 1 (<1) 1 (<1) 1 (1) 0 4 (2)
Viral infection 0 4 (2) 3 (2) 3 (3) 0 10 (5)
Digestive system
Appetite lost 1 (10) 0 0 0 1 (4) 2 (1)
Bloating 1 (10) 0 0 0 0 1 (<1)
Nausea 4 (40) 8 (4) 4 (2) 5 (5) 0 21 (10)
Vomiting 1 (10) 1 (<1) 0 1 (1) 0 3 (1)
Nervous system
Anxiety 1 (10) 1 (<1) 3 (2) 0 0 5 (2)
Concentration impaired 1 (10) 1 (<1) 0 0 0 2 (1)
Dizziness 1 (10) 4 (2) 4 (2) 4 (4) 0 11 (5)
Sedation excessive 1 (10) 1 (<1) 0 1 (1) 0 3 (1)
Unresponsive 1 (10) 0 0 0 0 1 (<1)
Respiratory system
Sinusitis 2 (20) 4 (2) 2 (1) 1 (1) 0 9 (4)
Special senses
Otitis media 1 (10) 0 0 0 0 1 (<1)
Urogenital system
Enuresis 0 0 3 (2) 0 2 (7) 5 (2)
Urinary tract infection 1 (10) 0 1 (1) 0 3 (1)
AEs, adverse events; SXB, sodium oxybate.
a Patients who reported ≥1 AE.
b Does not include one patient who experienced high blood pressure that was not recorded as an AE.
c Does not include two patients whose AEs occurred predose and one patient whose AEs were not captured in the summary tables because the patient’s AEs were not
associated with a dose.
d ≥ 5% at any dose level (Coding Symbols for a Thesaurus of Adverse Reaction Terms).
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improved” at week 12 appeared dose dependent as indicated by
overall signiﬁcance across doses (p = 0.029); the proportions at week
6 showed no difference across doses (p = 0.263).
The majority of patients reported reductions from baseline in
the core narcolepsy symptoms assessed by the items on the NSAQ
(Fig. 2) at week 6, and these effects were maintained at week 12.
The “Number of cataplexy attacks” was reduced in the highest pro-
portion of patients at both time points, 87% and 85%, respectively.
The proportions of patients reporting a decrease in each of the other
symptoms ranged from 61% to 73% at week 6 and 67% to 72% at week
12 (Fig. 2). When evaluated by last dose (Table 3), the majority of
patients at each dose also reported improvements in the individ-
ual core narcolepsy NSAQ items except for “Number of daily
inadvertent naps or sleep attacks” at week 6 and “Number of awak-
enings at night” at week 12 with 3 g/night.
On the “Quality of sleep” item, 87% and 85% of all patients re-
ported “much improved” or “somewhat improved” at week 6
(Fig. 3A) and week 12 (Fig. 3B), respectively. Among all patients, 70%
reported improvement in “Ability to concentrate” at week 6 (Fig. 4A)
and 74% reported improvement at week 12 (Fig. 4B).
4. Discussion
This open-label study supports and extends previous clinical trial
results on the safety and eﬃcacy of SXB. The 12-week duration
enabled assessment over a longer treatment period than during the
4- to 8-week registration trials. Across doses, SXB was well toler-
ated, and 85% of patients continued medication through the end
of study with 4% of patients discontinuing due to AEs. No new safety
signals were observed, and the safety and tolerability were consis-
tent with the parent studies [19,22,24] as well as with the known
safety proﬁle of SXB [18]; the most frequent AEs were those that
have previously been reported with SXB.
Assessment of doses showed that most of the adjustments were
increases due to lack of eﬃcacy, and these dose adjustments may
also have been required as a result of differences in body size;
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Fig. 1. Percent responders, deﬁned as patients who reported overall symptoms “somewhat improved” or “much improved” on the Narcolepsy Symptom Assessment Ques-
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patients receiving the higher doses appeared to be heavier and
taller (Table 1). There were few adjustments to a lower dose, and
as expected, many of these reductions were due to AEs. Two percent
of patients received the lowest dose, 3 g/night, as their ﬁnal dose,
indicating that down-titration to this dose due to AEs in a subset
of patients may resolve issues of tolerability. It is interesting to note
that all patients who received the 3 g/night dose as their ﬁnal dose
were female and had substantially lower weight than patients taking
higher doses. However, there were few patients in this group, it was
diﬃcult to interpret these results. Nevertheless, among the other
doses, 73% of patients had doses of 6–7.5 g/night, and the eﬃcacy
results further suggest that titration to effect during treatment with
SXB can help achieve a response for all core narcolepsy symptoms
in substantial proportions of patients.
Eﬃcacy in this study was evaluated using the NSAQ, a patient-
reported measure, which provides a perspective that may be more
clinically relevant for making treatment decisions than objective as-
sessment measures. Using the NSAQ, an overall high rate of response
to treatment was observed after 6 weeks and was maintained at
12 weeks, at which time 60% had also reported they were “much
improved” relative to baseline. Additionally, patients reported
improvement across the range of individual core and associated
symptoms. Several of the symptoms evaluated by the NSAQ,
including nocturnal awakenings (DNS) and quality of sleep, are
primary sources of patient complaints and contribute to the patient
burden. Of note is that there was a high response rate at 6 weeks
for improvement in ability to concentrate, 59–84% across the doses
(Fig. 4A), which was maintained at the lower doses and increased
at the higher doses at 12 weeks. There are few data on the ability
to concentrate among patients with narcolepsy, but studies have
suggested that narcolepsy patients have attention deﬁcits includ-
ing alterations in the executive control of attention [25,26]. Thus,
these preliminary results regarding concentration and the effects
of SXBwarrant further investigation. Although symptoms other than
cataplexy and EDS are less frequently assessed, the results re-
ported are consistent with the few data that are available on the
effects of SXB on those other symptoms [19,22,27–29].
4.1. Limitations
The main limitation of the current study is that it was of open-
label design with no comparator group. As subjective outcome
Table 3
Patients who reported reductions from baseline in core narcolepsy symptoms on the Narcolepsy Symptom Assessment Questionnaire by last sodium oxybate dose.
Symptom Patients with reduction in symptoms, n (%)
Week 6 Week 12
3 g
(n = 6)
4.5 g
(n = 17)
6 g
(n = 64)
7.5 g
(n = 60)
9 g
(n = 16)
3 g
(n = 5)
4.5 g
(n = 24)
6 g
(n = 69)
7.5 g
(n = 59)
9 g
(n = 19)
Number of cataplexy attacks 5 (83) 15 (88) 57 (89) 51 (85) 13 (81) 3 (60) 20 (83) 56 (81) 52 (88) 18 (95)
Number of daily inadvertent
naps or sleep attacks
2 (33) 11 (65) 45 (70) 46 (77) 9 (56) 3 (60) 16 (67) 47 (68) 47 (80) 14 (74)
Severity of daytime sleepiness 4 (67) 12 (75)a 47 (75)b 45 (75) 9 (56) 4 (80) 17 (71) 47 (68) 44 (75) 13 (68)
Number of awakenings at night 4 (67) 10 (59) 44 (69) 39 (65) 9 (56) 2 (40) 13 (54) 48 (70) 42 (71) 15 (79)
Number of hypnagogic
hallucinations
4 (67) 12 (71) 41 (64) 40 (67) 11 (69) 3 (60) 13 (54) 52 (75) 40 (68) 15 (79)
Number of sleep paralysis
episodes
4 (67) 12 (71) 37 (58) 35 (59)c 11 (69) 3 (60) 12 (50) 50 (74)d 37 (64)e 14 (74)
a n = 16.
b n = 63.
c n = 59.
d n = 68.
e n = 58.
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Fig. 3. Patients who reported improvements from baseline on the Quality of Sleep item of the Narcolepsy Symptom Assessment Questionnaire: (A) Week 6; (B) Week 12.
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measures were used, it is not possible to identify the component
of change due to treatment effect versus that due to “placebo” effect,
regression to the mean, or some other effect. Another key limita-
tion results from the ﬂexible dose-titration process; patients’ doses
were increased or decreased as needed to optimize eﬃcacy and
tolerability. Consequently, this study provides no capacity to allow
deﬁnitive conclusions regarding the potential dose–response func-
tion of SXB for either eﬃcacy or safety. Additionally, the NSAQ has
not been formally validated and provides qualitative data only.
However, the NSAQ does include items covering all core narcolep-
sy symptoms as well as two items on outcomes of importance to
patients (sleep quality and attention), and has been previously used
with results similar to those reported here [19]. Another limita-
tion is that patient responses may be subject to recall bias, since
the recall period for NSAQ responses was the previous week, and
was with respect to baseline, 6 weeks, and 12 weeks prior to the
assessment; longer recall periods have a greater risk for bias than
shorter recall periods. Finally, evaluable data for the 3 g/night dose
were limited by the small sample size, although the low number
of patients in this dose group also suggests that there were few pa-
tients who required such a dose reduction due to AEs.
5. Conclusions
The safety proﬁle of SXB in this open-label study was consis-
tent with previous safety ﬁndings from double-blind clinical trials.
Patient self-report indicated improvement at 6 and 12 weeks across
the range of narcolepsy symptoms, with most patients deemed re-
sponders based on the predeﬁned NSAQ response deﬁnition; the
majority of patients were much improved, and this improvement
was dose dependent. Additionally, patients reported improve-
ment in sleep quality and ability to concentrate, outcomes that
generally have not been evaluated in clinical trials.
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